Unnati Pharmax

Hetronifly Injection
Composition: Serplulimab Concentrate for Solution for Infusion 10 mg/mL

Hetronifly is a high-quality Serplulimab 10 mg/mL Concentrate for Solution for Infusion, a humanized monoclonal antibody designed to enhance immune-mediated anti-tumor activity. It is developed as an advanced immunotherapy option and is manufactured in WHO-GMP certified facilities. Hetronifly Injection is supplied by trusted pharmaceutical exporters from India to support modern global oncology treatment programs.

Serplulimab is a programmed death-1 (PD-1) immune checkpoint inhibitor that works by blocking the interaction between the PD-1 receptor on T-cells and its ligands, PD-L1 and PD-L2, on tumor cells. This mechanism helps restore the body’s natural immune response against cancer, enabling T-cells to recognize and attack malignant cells more effectively. Hetronifly is primarily indicated for the treatment of various advanced and metastatic malignancies, as per approved clinical indications, where immunotherapy has shown significant clinical benefit.

Hetronifly Serplulimab Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent safety, potency, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Mycocept 500 Tablets
Composition: Mycophenolate Mofetil Tablets IP 500 mg

Mycocept 500 is a high-quality Mycophenolate Mofetil Tablets IP 500 mg formulation, developed as an effective immunosuppressive therapy for the prevention of organ transplant rejection. Manufactured in WHO-GMP certified facilities, Mycocept 500 is supplied by trusted pharmaceutical exporters from India to support advanced global transplant care and immunosuppressive treatment programs.

Mycophenolate mofetil is a prodrug of mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme required for the proliferation of T and B lymphocytes. By suppressing lymphocyte activation and proliferation, Mycocept 500 helps prevent immune-mediated damage to transplanted organs while maintaining a favorable safety profile. It is primarily indicated for the prophylaxis of organ rejection in patients undergoing kidney, heart, or liver transplantation, and is often used in combination with other immunosuppressive agents such as corticosteroids and calcineurin inhibitors.

Mycocept 500 Tablets are manufactured under stringent GMP and quality assurance standards, ensuring consistent potency, safety, and long-term stability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for transplant centers, tertiary care hospitals, specialty clinics, government healthcare programs, and international pharmaceutical distributors.